PT-141 for low libido on GLP-1 drugs

A question that keeps appearing in peptide communities: women on retatrutide or other GLP-1 class drugs reporting a drop in sexual desire, and asking whether adding PT-141 (bremelanotide) or kisspeptin might help. The short answer is that PT-141 is an FDA-approved medicine for a specific indication in premenopausal women and has the strongest evidence base here. Kisspeptin is still experimental and does not yet have a licensed product. Neither replaces a conversation with a clinician if the side effect is affecting your quality of life.

Do GLP-1 class drugs reduce libido?

The published literature is thin on this question. Retatrutide is still investigational and has not been approved by the FDA, EMA, or MHRA^[1]. Its large Phase 3 trial (TRIUMPH-1) did not report sexual-function endpoints as primary or secondary outcomes, so there is no trial-level data linking retatrutide specifically to libido changes.

What is better documented is the indirect pathway. GLP-1 class medicines often reduce caloric intake sharply and trigger rapid weight loss. Significant caloric restriction can lower estrogen and androgen levels, which affects sexual desire in women. There is also a natriuretic and fluid-reduction effect early in treatment that can cause fatigue, and fatigue is one of the most common contributors to low libido. Community reports of reduced sex drive during GLP-1 class treatment are plausible through these mechanisms even if head-to-head trial data for retatrutide specifically does not exist.

A 2026 narrative review in Sexual Medicine Reviews concluded that GLP-1 receptor agonists' effects on female sexual function "remain largely uncharacterized" and called for dedicated trials, noting that preclinical and observational signals go in both directions depending on weight-loss magnitude and hormonal status.

PT-141 (bremelanotide): what it is and what the evidence actually shows

Bremelanotide, sold in the United States as Vyleesi, is the only FDA-approved non-hormonal treatment specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women^[2]. The FDA approved it in 2019 under NDA 210557. It is not approved by the EMA or the MHRA, meaning there is no authorized product in the EU, EEA, or UK.

It works as a melanocortin receptor agonist, binding primarily to MC3R and MC4R in the central nervous system^[3]. The exact mechanism by which this translates to increased sexual desire is not fully established. The RECONNECT Phase 3 programme (two placebo-controlled trials, approximately 1,247 participants) showed statistically significant improvement in sexual desire scores and reduction in distress on the FSFI desire domain and FSDS-DAO item 13 versus placebo. Effect sizes are described as modest in the label.

The approved dose is 1.75 mg subcutaneously (abdomen or thigh) at least 45 minutes before anticipated sexual activity, no more than once per 24 hours, and no more than 8 doses per month^[3]. The most common adverse event is nausea, affecting roughly 40% of treated women in trials, with flushing (20%), injection site reactions (13%), and headache (11%) also frequently reported. A small number of women develop focal hyperpigmentation that may not fully resolve. The drug is contraindicated in people with uncontrolled hypertension or known cardiovascular disease because it transiently raises blood pressure (mean 6 mmHg systolic) and lowers heart rate.

The critical regulatory point: if you are outside the United States, there is no authorized Vyleesi product. Grey-market vials sold online as 'PT-141' or 'bremelanotide' are not FDA-regulated products and importing them is restricted. Anyone in the EU, EEA, or UK pursuing this route would be doing so outside licensed channels.

What kisspeptin is and where the evidence stands

Kisspeptin is a neuropeptide that activates gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus, triggering the downstream release of LH and FSH and stimulating sex hormone production. That central role in reproductive signaling is why researchers have studied it as a potential treatment for sexual desire disorders.

The human evidence is promising but early. A randomized clinical trial (PMID 36287566) published in 2022 investigated kisspeptin administration in women with HSDD and found signals of enhanced sexual brain processing. A parallel trial in men with HSDD (PMID 36735255) found similar effects on sexual brain activity and penile tumescence. A 2025 review (PMID 40189467) summarised the research as showing kisspeptin activates brain regions associated with sexual and emotional processing in humans, while noting that no product is licensed for this indication anywhere.

There is no approved kisspeptin product for human use for sexual desire or any other indication as of August 2026. Research is conducted through academic clinical programmes, not commercial supply chains. Grey-market kisspeptin peptide vials are not from these trials and are not authorized products.

How these two options compare for someone on retatrutide

PT-141 (bremelanotide) has the clearer evidence base and is the only one with regulatory approval for the specific indication, albeit only in the US. For a premenopausal woman with acquired, generalized HSDD who meets the clinical definition, it is the only centrally-acting option with approved-label support. The adverse-event profile, particularly nausea and the cardiovascular contraindications, needs to match the individual's situation. A clinician familiar with both the GLP-1 treatment and sexual health medicine is the right person to weigh this.

Kisspeptin is not ready for general use. The human trials showing effects on brain sexual processing are real, but they are academic proof-of-concept studies, not a licensed treatment path. There is no standardized dose, no approved formulation, and no commercial product that replicates what the trials used.

A step that sometimes gets overlooked: if libido dropped significantly after starting retatrutide or any GLP-1 class drug, it is worth discussing with the prescribing clinician whether the caloric deficit, rapid weight change, or any nutritional gap is contributing. Correcting those factors may help before adding a separate peptide.

What we do not yet know

There is no published randomized trial specifically on retatrutide and sexual function. There is no trial directly comparing PT-141 with kisspeptin in any population. The interaction between GLP-1 class mechanisms and melanocortin signaling has not been studied in humans. The durability of kisspeptin's effects on sexual desire in a sustained treatment model is unknown. The literature on how weight loss magnitude affects female sexual desire specifically in GLP-1 treated populations is sparse.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.